Sunday, February 04, 2024 3:16:43 PM
[url]https://www.gene.com/patients/disease-education/amd-fact-sheet#:~:text=Wet%20AMD%20accounts%20for%20approximately,90%20percent%20of%20legal%20blindness.&text=Wet%2C%20or%20neovascular%2C%20AMD%20is,rapid%20and%20severe%20vision%20loss.
[/url][tag]About[/tag]
References
1 National Eye Institute. Age-related macular degeneration: What You Should Know. National Eye Institute:
NIH publication 03-2294. Available at: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration#section-id-7325. Accessed February 3, 2023.
2 BrightFocus Foundation. Age-Related Macular Degeneration: Facts & Figures. Available at: https://www.brightfocus.org/macular/article/age-related-macular-facts-figures. Accessed February 3, 2023.
3 Jager RD, Mieler WF, Miller JW. Age-Related macular degeneration. New England Journal of Medicine. 2008; 358:2606-2617
4 American Academy of Ophthalmology. What is Macular Degeneration?. Available at: https://www.aao.org/eye-health/diseases/amd-macular-degeneration. Accessed February 3, 2023.
5 JAMA Ophthalmology. Original Investigation: Prevalence of Age-Related Macular Degeneration in the US in 2019. Available at: https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2797921. Accessed February 3, 2023.
6 Maguire MG. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost. Issue Brief. 2012;17(8). Leonard Davis Institute of Health Economics. Accessed February 7, 2020. https://ldi.upenn.edu/wp-content/uploads/archive/pdf/Issue%20Brief%2017_8.pdf
7 National Eye Institute.Age-Related Macular Degeneration: NEI Looks Ahead. States. Available at: https://medialibrary.nei.nih.gov/search?keywords=&f%5B0%5D=category%3A4#/media/1777. Accessed February 3, 2023.
8 BrightFocus Foundation. Macular Degeneration: Essential Facts. Available at: https://www.brightfocus.org/macular/news/macular-essential-facts. Accessed February 3, 2023.
Recent EYPT News
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/18/2024 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 06:53:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:05:09 PM
- EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:40:53 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:01:44 PM
- EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:08:48 PM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/16/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:08:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:40:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:39:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:38:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:38:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 10:37:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 05:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 10:15:56 PM
- EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration • GlobeNewswire Inc. • 02/03/2024 09:20:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2024 09:22:27 PM
- EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM